The economic burden of metastatic breast cancer: A systematic review of literature from developed countries

Cancer Treatment Reviews

Volumn 37, Issue 6, 2011, Pages 405-415

  Foster, Talia S ^a   Miller, Jeffrey D ^a   Boye, Mark E ^b   Blieden, Marissa B ^a   Gidwani, Risha ^a   Russell, Mason W ^a  

^a Abt Bio Pharma Solutions Inc   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Cost effectiveness; Cost of illness; Costs; Economic burden; Metastatic breast cancer; Multi country economic evaluation; Systematic review

Indexed keywords

ANASTROZOLE; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; FULVESTRANT; GEMCITABINE; IXABEPILONE; LAPATINIB; LETROZOLE; METHOTREXATE; NAVELBINE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

AUSTRALIA; BREAST CANCER; CANADA; CANCER SURVIVAL; CLINICAL TRIAL; COST MINIMIZATION ANALYSIS; DRUG COST; FRANCE; GOVERNMENT; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; ITALY; METASTASIS; REVIEW; SWEDEN; SYSTEMATIC REVIEW; UNITED KINGDOM; UNITED STATES;

BREAST NEOPLASMS; DEVELOPED COUNTRIES; FEMALE; HUMANS; NEOPLASM METASTASIS;

EID: 79960972522     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.12.008     Document Type: Review

References (80)

1. Beslija S., Bonneterre J., Burstein H., et al. Second consensus on medical treatment of metastatic breast cancer - CECOG guidelines. Ann Oncol 2007, 18(2):215-225.
2. CDC, US Cancer Statistics Working Group. Top 10 Causes of Death for Women in the United States (2003). CDC Statistics; 2007.
3. World Health Organization. Cancer. Fact sheet No. 297: World Health Organization; 2006.
4. Greenberg P.A., Hortobagyi G.N., Smith T.L., Ziegler L.D., Frye D.K., Buzdar A.U. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996, 14(8):2197-2205.
5. Singletary S.E., Greene F.L. Revision of breast cancer staging: the 6th edition of the TNM Classification. Semin Surg Oncol 2003, 21(1):53-59.
6. Banning M. Advanced breast cancer: aetiology, treatment and psychosocial features. Br J Nurs 2007, 16(2):86-90.
7. American Cancer S. Cancer Facts & Figures 2007. Atlanta: American Cancer Society; 2007.
8. Commission on Cancer - National Cancer Database. Benchmark Reports, V 8.0 - August 20, 2007 - STAGE of Breast Cancer Diagnosed in 2004: Commission on Cancer - National Cancer Database (NCDB); 2007.
9. Jatoi I., Chen B.E., Anderson W.F., Rosenberg P.S. Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol 2007, 25(13):1683-1690.
10. El Saghir N.S., Seoud M., Khalil M.K., et al. Effects of young age at presentation on survival in breast cancer. BMC Cancer 2006, 6:194.
11. Puglisi F., Follador A., Minisini A.M., et al. Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol 2005, 16(2):263-266.
12. Remak E., Brazil L. Cost of managing women presenting with stage IV breast cancer in the United Kingdom. Br J Cancer 2004, 91(1):77-83.
13. Sant M., Allemani C., Capocaccia R., et al. Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. Int J Cancer 2003, 106(3):416-422.
14. Schneider C., Fehr M.K., Steiner R.A., Hagen D., Haller U., Fink D. Frequency and distribution pattern of distant metastases in breast cancer patients at the time of primary presentation. Arch Gynecol Obstet 2003, 269(1):9-12.
15. Traina A., Cusimano R., Liquori M., et al. Breast cancer incidence in the city and province of Palermo in 1999-2002: a Breast Cancer Registry report. Ann NY Acad Sci. 2004, 1028:473-480.
16. Access Economics. Management of metastatic breast cancer: an examination of socioeconomic and regional impacts 2007.
17. Efficace F., Biganzoli L., Piccart M., et al. Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer 2004, 40(7):1021-1030.
18. Engel J., Eckel R., Aydemir U., et al. Determinants and prognoses of locoregional and distant progression in breast cancer. Int J Radiat Oncol Biol Phys 2003, 55(5):1186-1195.
19. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics, 1999. CA Cancer J Clin 1999, 49(1):8-31.
20. Colozza M., de Azambuja E., Personeni N., Lebrun F., Piccart M.J., Cardoso F. Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. Oncologist 2007, 12(3):253-270.
21. Dodwell D., Wardley A., Johnston S. Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors. Breast 2006, 15(5):584-594.
22. Smith I. Goals of treatment for patients with metastatic breast cancer. Semin Oncol 2006, 33(1, Suppl. 2):S2-S5.
23. von Minckwitz G. Evidence-based treatment of metastatic breast cancer - 2006 recommendations by the AGO Breast Commission. Eur J Cancer 2006, 42(17):2897-2908.
24. Gradishar W. Fulvestrant in the treatment of postmenopausal women with advanced breast cancer. Expert Rev Anticancer Ther 2005, 5(3):445-453.
25. Gralow J.R. Optimizing the treatment of metastatic breast cancer. Breast Cancer Res Treat 2005, 89(Suppl 1):9-15.
26. Clemens M, Kaufman B, Mackey JR, et al. Trastuzumab plus anastrozole may prolong overall survival in postmenopausal women with HER2-positive, hormone-dependent metastatic breast cancer: results of a post-hoc analysis from the TAnDEM study. Abstract 231 at 2007 Breast Cancer Symposium 2007.
27. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. 2010.
28. Sassi F., Archard L., McDaid D. Searching literature databases for health care economic evaluations: how systematic can we afford to be?. Med Care 2002, 40(5):387-394.
29. Gold M.R., Siegel J.E., Russel L.B., Weinsten M.C. Cost-effectiveness in health and medicine 1996, Oxford University Press, Oxford.
30. Lidgren M., Wilking N., Jonsson B., Rehnberg C. Resource use and costs associated with different states of breast cancer. Int J Technol Assess Health Care 2007, 23(2):223-231.
31. Drucker A., Skedgel C., Virik K., Rayson D., Sellon M., Younis T. The cost burden of trastuzumab and bevacizumab therapy for solid tumours in Canada. Curr Oncol 2008, 15(3):136-142.
32. Poncet B., Colin C., Bachelot T., et al. Treatment of metastatic breast cancer: a large observational study on adherence to French prescribing guidelines and financial cost of the anti-HER2 antibody trastuzumab. Am J Clin Oncol 2009, 32(4):369-374.
33. Rao S., Kubisiak J., Gilden D. Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat 2004, 83(1):25-32.
34. Kruse G.B., Amonkar M.M., Smith G., Skonieczny D.C., Stavrakas S. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a US population. J Manag Care Pharm 2008, 14(9):844-857.
35. Camacho F.T., Wu J., Wei W., Kimmick G., Anderson R.T., Balkrishnan R. Cost impact of oral capecitabine compared to intravenous taxane-based chemotherapy in first-line metastatic breast cancer. J Med Econ 2009, 12(3):238-245.
36. Ho J., Zhang L., Todorova L., Whillans F., Corey-Lisle P., Yuan Y. Budget impact analysis of ixabepilone used according to FDA approved labeling in treatment-resistant metastatic breast cancer. J Manag Care Pharm 2009, 15(6):467-475.
37. Delea T., McKiernan J., Brandman J., et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 2006, 4(7):341-347.
38. Pelletier E.M., Shim B., Goodman S., Amonkar M.M. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis. Breast Cancer Res Treat 2008, 108(2):297-305.
39. Pearson S.A., Ringland C.L., Ward R.L. Trastuzumab and metastatic breast cancer: trastuzumab use in Australia-monitoring the effect of an expensive medicine access program. J Clin Oncol 2007, 25(24):3688-3693.
40. Grunfeld E., Coyle D., Whelan T., et al. Family caregiver burden: results of a longitudinal study of breast cancer patients and their principal caregivers. CMAJ 2004, 170(12):1795-1801.
41. Lidgren M., Wilking N., Jonsson B. Cost of breast cancer in Sweden in 2002. Eur J Health Econ. 2007, 8:5-15.
42. Shih YC, Elting LS, Pavluck AL, Stewart A, Halpern MT. Immunotherapy in the initial treatment of newly diagnosed cancer patients: utilization trend and cost projections for non-Hodgkin's lymphoma, metastatic breast cancer, and metastatic colorectal cancer. Cancer Invest 2010;28(1):46-53.
43. Dranitsaris G., Cottrell W., Spirovski B., Hopkins S. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer. J Oncol Pharm Pract 2009, 15(2):67-78.
44. Vu T., Ellard S., Speers C.H., et al. Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: a population-based evaluation. Ann Oncol 2008, 19(3):461-464.
45. Perez-Ellis C., Goncalves A., Jacquemier J., et al. Cost-effectiveness analysis of trastuzumab (Herceptin) in HER2-overexpressed metastatic breast cancer. Am J Clin Oncol. 2009.
46. Lux M.P., Hartmann M., Jackisch C., et al. Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model. Breast Cancer Res Treat 2009, 117(2):305-317.
47. Bocci G., Tuccori M., Emmenegger U., et al. Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann Oncol 2005, 16(8):1243-1252.
48. Marchetti M., Caruggi M., Colombo G. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service. Clin Ther 2004, 26(9):1546-1561.
49. Lidgren M., Wilking N., Jonsson B., Rehnberg C. Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer. Acta Oncol 2008, 47(6):1018-1028.
50. Dedes K.J., Matter-Walstra K., Schwenkglenks M., et al. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. Eur J Cancer 2009, 45(8):1397-1406.
51. Matter-Walstra KW, Dedes KJ, Schwenkglenks M, Brauchli P, Szucs TD, Pestalozzi BC. Trastuzumab beyond progression: a cost-utility analysis. Ann Oncol 2010.
52. Benedict A., Cameron D.A., Corson H., Jones S.E. An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK. Pharmacoeconomics 2009, 27(10):847-859.
53. Cameron D.A., Camidge D.R., Oyee J., Hirsch M. Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer. Br J Cancer 2008, 99(12):1984-1990.
54. Dranitsaris G, Coleman R, Gradishar W. nab-Paclitaxel weekly or every 3weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial. Breast Cancer Res Treat. 2010;119(3):717-724.
55. National Institute for Health and Clinical Excellence. Guidance on the use of trastuzumab for the treatment of advanced breast cancer. (Technology Appraisal No. 34). London (UK): National Institute for Clinical Excellence (NICE); 2002.
56. National Institute for Health and Clinical Excellence. Gemcitabine for the treatment of metastatic breast cancer. (Technology appraisal guidance 116). London (UK): National Institute for Clinical Excellence (NICE); 2007.
57. Takeda A.L., Jones J., Loveman E., Tan S.C., Clegg A.J. The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation. Health Technol Assess 2007, 11. (19).
58. Jones J., Takeda A., Tan S.C., Cooper K., Loveman E., Clegg A. Gemcitabine for the treatment of metastatic breast cancer. Health Technol Assess 2009, 13(Suppl 2):1-7.
59. Jones J., Takeda A., Picot J., von Keyserlingk C., Clegg A. Lapatinib for the treatment of HER2-overexpressing breast cancer. Health Technol Assess 2009, 13(Suppl 3):1-6.
60. National Institute for Health and Clinical Excellence. Advanced breast cancer: diagnosis and treatment. 2009.
61. Le Q.A., Hay J.W. Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. Cancer 2009, 115(3):489-498.
62. Reed S.D., Li Y., Anstrom K.J., Schulman K.A. Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2009, 27(13):2185-2191.
63. Verma S., Maraninchi D., O'Shaughnessy J., et al. Capecitabine plus docetaxel combination therapy. Cancer 2005, 103(12):2455-2465.
64. Blank PR, Dedes KJ, Szucs TD. Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review. Pharmacoeconomics 2010;28(8):629-647.
65. Muening P. Designing and conducting cost-effectiveness analyses in medicine and health care 2002, Jossey-Bass, San Francisco, CA.
66. Imai H., Kuroi K., Ohsumi S., Ono M., Shimozuma K. Economic evaluation of the prevention and treatment of breast cancer-present status and open issues. Breast cancer 2007, 14(1):81-87.
67. Lwin Z., Leighl N. Economic evaluation of docetaxel for breast cancer. Expert Opin Pharmacother 2009, 10(2):283-290.
68. National Institute for Health and Clinical Excellence. Guidance on the use of vinorelbine for the treatment of advanced breast cancer. (Technology appraisal guidance; No. 54). London (UK): National Institute for Clinical Excellence (NICE); 2002.
69. Ferrusi I.L., Marshall D.A., Kulin N.A., Leighl N.B., Phillips K.A. Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses. Per Med Mar 2009, 6(2):193-215.
70. Norum J., Risberg T., Olsen J.A. A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis. Ann Oncol 2005, 16(6):909-914.
71. Benedict A., Brown R.E. Review of cost-effectiveness analyses in hormonal therapies in advanced breast cancer. Expert Opin Pharmacother 2005, 6(11):1789-1801.
72. Karnon J. Cost-effectiveness of letrozole in the treatment of advanced breast cancer. Expert Rev Pharmacoeconomics Outcomes Res 2004, 4(4):383-391.
73. Karnon J. Aromatase inhibitors in breast cancer: a review of cost considerations and cost effectiveness. Pharmacoeconomics 2006, 24(3):215-232.
74. Lonning P.E., Geisler J. Aromatase inhibitors-socio-economical issues. J Steroid Biochem Mol Biol 2005, 95(1-5):137-142.
75. Gibson L.J., Dawson C.K., Lawrence D.H., Bliss J.M. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev 2007, (1):CD003370.
76. Marty M., Cognetti F., Maraninchi D., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005, 23(19):4265-4274.
77. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005, 10(Suppl. 3):20-29.
78. O'Shaughnessy J., Miles D., Vukelja S., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002, 20(12):2812-2823.
79. Jang S, Chae YK, Haddad T, Majhail NS. Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review. Breast Cancer Res Treat 2010;121(2):273-279.
80. Weinstein M.C., O'Brien B., Hornberger J., et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices-modeling studies. Value Health 2003, 6(1):9-17.